000			02934cam a2200349Ia 4500
001			CRC0KE11133PDF
003			BD-DhSAU
005			20151012144309.0
006			m|||||o||d||||||||
007			cr||||
008			100602s2011 flu sb 001 0 eng d
020			_a9781439825518 (ebook : PDF)
040			_aBD-DhSAU _cBD-DhSAU
090			_aR853.C55 _bB385 2011
092			_a615.50724 _bB357
245	0	0	_aBayesian adaptive methods for clinical trials _h[electronic resource] / _cScott M. Berry ... [et al.].
260			_aBoca Raton : _bChapman & Hall/CRC, _c2011.
300			_a323 p.
490	1		_aChapman & Hall/CRC biostatistics series ; _v38
504			_aIncludes bibliographical references and indexes.
505	0		_a(Publisher-supplied data) Statistical approaches for clinical trials -- Basics of Bayesian inference -- Phase I studies -- Phase II studies -- Phase III studies -- Special topics.
520			_a"As has been well-discussed, the explosion of interest in Bayesian methods over the last 10 to 20 years has been the result of the convergence of modern computing power and e�cient Markov chain Monte Carlo (MCMC) algo- rithms for sampling from and summarizing posterior distributions. Prac- titioners trained in traditional, frequentist statistical methods appear to have been drawn to Bayesian approaches for three reasons. One is that Bayesian approaches implemented with the majority of their informative content coming from the current data, and not any external prior informa- tion, typically have good frequentist properties (e.g., low mean squared er- ror in repeated use). Second, these methods as now readily implemented in WinBUGS and other MCMC-driven software packages now oʼer the simplest approach to hierarchical (random eʼects) modeling, as routinely needed in longitudinal, frailty, spatial, time series, and a wide variety of other settings featuring interdependent data. Third, practitioners are attracted by the greater �exibility and adaptivity of the Bayesian approach, which permits stopping for e�cacy, toxicity, and futility, as well as facilitates a straightforward solution to a great many other specialized problems such as dose-nding, adaptive randomization, equivalence testing, and others we shall describe. This book presents the Bayesian adaptive approach to the design and analysis of clinical trials"--Provided by publisher.
530			_aAlso available in print edition.
538			_aMode of access: World Wide Web.
650		0	_aClinical trials _xStatistical methods.
650		0	_aBayesian statistical decision theory.
655		7	_aElectronic books. _2lcsh
700	1		_aBerry, Scott M.
776	1		_z9781439825488
830		0	_aChapman & Hall/CRC biostatistics series ; _v38.
856	4	0	_uhttp://marc.crcnetbase.com/isbn/9781439825518 _qapplication/PDF
999			_c12122 _d12121